Europe is Going for Blood

Europe has a roadblock in its quest for pharmaceutical self-sufficiency: a reliance on American blood plasma.
Blood plasma is a crucial element in developing drugs, and that includes experimental COVID-19 treatments.
But while US donors are paid for donating blood used for drug R&D; most Europeans aren’t because of safety and ethical concerns. That leaves Europe vulnerable to sudden supply interruptions, a possibility that has come into sharp relief as the pandemic boosts demand while lockdowns keep would-be donors away.
At an EU meeting last week, blood experts discussed strategies for the bloc to be more self-sufficient when it comes to pharmaceuticals.   

Secondary Topic
Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top